COMT inhibitor. Inhibits both brain and peripheral COMT. Also binds transthyretin (TTR) with high affinity (Kd1 and Kd2 values are 21 and 58 nM, respectively). Inhibits TTR aggregation in human plasma and prevents TTR-induced cytotoxicity in vitro. Stabilizes TTR in mice and humans in vivo. Orally bioavailable.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 273.24. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.66 mL||18.3 mL||36.6 mL|
|5 mM||0.73 mL||3.66 mL||7.32 mL|
|10 mM||0.37 mL||1.83 mL||3.66 mL|
|50 mM||0.07 mL||0.37 mL||0.73 mL|
References are publications that support the biological activity of the product.
Sant'Anna et al (2016) Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat.Commun. 7 10787 PMID: 26902880
Männistö et al (1992) Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br.J.Pharmacol. 105 569 PMID: 1628144
If you know of a relevant reference for Tolcapone, please let us know.
View Related Products by Product Action
Keywords: Tolcapone, Tolcapone supplier, catechol, O-methyl, transferase, inhibitors, inhibits, COMT, orally, bioavailable, high, affinity, TTR, binding, transthyretin, aggregation, Ro40-7592, Tasmar, Ro, 40-7592, Catechol, O-Methyltransferase, 5864, Tocris Bioscience
Citations for Tolcapone
Citations are publications that use Tocris products.
Currently there are no citations for Tolcapone. Do you know of a great paper that uses Tolcapone from Tocris? Please let us know.
Reviews for Tolcapone
There are currently no reviews for this product. Be the first to review Tolcapone and earn rewards!
Have you used Tolcapone?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.